WORLDCOIN-FOUNDATION
The Worldcoin Foundation today announced it launched and is open sourcing a novel secure multi-party computation (SMPC) system. The system, available now in a GitHub repository for any organization to use, aims to set a new standard for data protection, including the protection of biometric data. The Worldcoin Foundation also announced that, after the migration of iris codes to the new SMPC system, the previous uniqueness-checking system, including iris codes, was securely deleted.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515285506/en/
Worldcoin Foundation Launches, Open Sources "Perfect Secrecy" SMPC System to Help Organizations Strengthen Biometric Data Security Protections (Graphic: Business Wire)
Biometric authentication use increases as data breach frequency and impact rise
Organizations in the private and public sector increasingly require and use consumers’ biometric data for everyday services and activities, from building access and airport security to logging into healthcare and financial services apps. Underscoring the increase, a Fortune Business Insights report projected the global biometric system market size to reach $76.70 billion USD in 2029, 2.5x its total of $30.77 billion in 2022.
Meanwhile, research from MIT Professor Stuart Madnick indicates a 20% increase in data breaches from 2022 to 2023 while globally the number of victims of such breaches doubled over the same time period.
The convergence of these trends suggests a need to further advance data protection technologies. While Worldcoin is neither an authentication nor an identification use case for biometrics (the Worldcoin Foundation does not know the identity of their users), the Foundation’s new open source SMPC system can serve as a building block to set a new standard in biometric data security.
Worldcoin Foundation’s SMPC system
SMPC has been lauded by privacy and security experts alike. It can be thought of as taking one secret and sharing it in multiple parts across different parties for increased protection. Importantly, none of the individual parts alone say anything about the original secret, thus making it impossible for any individual party to decrypt the secret.
This SMPC approach demonstrates perfect information-theoretic security, meaning it is effective even against quantum-computing. SMPC systems have generally been too resource-intensive to be effectively used for large complex computations. This is why, despite their impressive privacy protective qualities, they have not yet seen extensive use in biometric template protection.
The Worldcoin Foundation, along with contributor-technologists from TACEO and Tools for Humanity, have successfully architected a new implementation of SMPC to address the scale and cost constraints that have previously hindered others. The new SMPC system, which encrypts iris codes into secret shares held by multiple parties, enabled the Worldcoin Foundation to permanently delete iris codes generated through its previous uniqueness-checking system.
“The community supporting Worldcoin will never stop developing, testing and deploying the most advanced technologies focusing on security, privacy and data protection as it works to improve trust online and increase access to the global economy,” said Jannick Preiwisch, Data Protection Officer of the Worldcoin Foundation. “Implementation of the new SMPC system enabled the Worldcoin Foundation to delete old iris codes by permanently encrypting them to SMPC shares that by themselves cannot be related to an identified person. The development of this new system demonstrates an unparalleled commitment to further compliance with the EU General Data Protection Regulation and other data protection regimes across the world. It also complements advancements aimed at providing consumers increased choice and control over their data including personal custody and the ability to unverify their World IDs.”
About the Worldcoin Foundation
The Worldcoin Foundation, a steward of the Worldcoin protocol, aims to realize more inclusive, fair and just institutions of governance and of the global digital economy.
About the Worldcoin Protocol
The Worldcoin protocol is intended to be the world’s largest, most inclusive identity and financial public utility and to be accessible by everyone. Worldcoin was originally conceived by Sam Altman, Alex Blania and Max Novendstern. The Worldcoin protocol is designed to empower individuals and organizations around the world with the tools they need to participate in the digital economy and advance humanity's progress. Find out more about Worldcoin at www.worldcoin.org, on Twitter/X, Discord, YouTube and Telegram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515285506/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom